XDEMVY® the treatment for Demodex

Did you know that there can be a host in your eyelashes?

If you didn’t know about it, let’s get you introduced: It’s called Demodex, and it’s a tiny mite. Demodex is part of our skin’s microbiome and is kept in check by our immune system. However, it may cause some affections.

Demodex is usually a harmless mite.

However, an infestation caused by it can lead to problems such as ocular rosacea, recurring styes or blepharitis (eyelid inflammation). If you are suffering symptoms such as eyelash dandruff, eye dryness, a feeling of strange particles in your eye, redness or irritation, Demodex may be the cause.

XDEMVY Targets and Kills the Mites

That Cause Demodex Blepharitis (DB)

XDEMVY was created specifically to treat Demodex blepharitis.

XDEMVY is the first and only FDA-approved treatment for DB.^1,2

• One drop per eye, twice a day, approximately 12 hours apart, in just 6 weeks

  In 2 combined studies, 50% of patients had a reduction of crusties (collarettes) and 60% of patients had their Demodex mites completely wiped out.³*

• Designed for patient comfort

  ~90% of patients in both trials reported XDEMVY eye drops as neutral to very comfortable to use.^3†

• Stay on top of your treatment

  It’s important to use XDEMVY for the full 6 weeks.

• Reduce eyelid redness

  Patients using XDEMVY for DB may see eyelid redness gone in just 6 weeks.^1,2

To receive more information about this treatment you can make an appointment or call us at the clinic.

References: 1. Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optometry. 2018;10:57-63. 2. Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311-318. 3. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-1164. 4. O’Dell L, Dierker DS, Devries DK, et al. Psychosocial impact of Demodex blepharitis. Clin Ophthalmol. 2022;16:2979-2987.

XDEMVY for Demodex blepharitis was evaluated in 2 pivotal trials of 833 patients (415 received XDEMVY).^2,4,5
Trial 1: When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 44% of patients (N=209) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 68% of patients (N=212) at Day 43.
Trial 2: When taken twice daily in each eye for 6 weeks, XDEMVY reduced collarettes to 2 or less for the upper eyelid in 55% of patients (N=193) at Day 43; XDEMVY eradicated mites (mite density of 0 mites/lash) in 50% of patients (N=203) at Day 43.

^†All visits averaged.³